FindTrial
Sign In

A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer.

A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer. - Induction therapy for N2 positive NSCLC

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000358
Enrollment
25
Registered
2006-04-01
Start date
2006-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Chemotherapy

Sponsors

Fukushima Medical University
Lead Sponsor
Fukushima Red cross hospitalIwaki public hospitalSouthern Tohoku general hospitalYonezawa city hospitalSirakawa kosei hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytological proved non-small cell lung cancer. 2. Performance status of 0 or 1 3.PET positive mediastinal node positive c-stage IIIA 4.Adequate bone marrow reserve, hepatic, renal functions, and normal cardiac function 5.Written informed consent is required to obtain from each patient at each participating institution

Exclusion criteria

Exclusion criteria: 1. active interstitial pneumonia 2. active infectious disease 3. active other cancer 4. severe drug allergy 5. severe complications

Design outcomes

Primary

MeasureTime frame
Response rate—

Secondary

MeasureTime frame
adverse event, over all survival, recurrence-free survival rate, effectiveness of evaluation by PET scan—

Countries

Japan

Contacts

Public ContactHiroyuki Suzuki

Fukushima Medical University Department of Surgery 1

hiro@fmu.ac.jp024-547-1254

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026